Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced. Methods: The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic's start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020–2022). Findings: The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or more doses, as well as encountering COVID-19 in 2022, were associated with improved survival. Interpretation: Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe COVID-19 cases. Funding: Not applicable.
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
Salmanton-Garcia J.;Marchesi F.;Farina F.;Weinbergerova B.;Itri F.;Davila-Valls J.;Martin-Perez S.;Glenthoj A.;Hersby D. S.;Gomes da Silva M.;Nunes Rodrigues R.;Lopez-Garcia A.;Cordoba R.;Bilgin Y. M.;Falces-Romero I.;El-Ashwah S.;Emarah Z.;Besson C.;Kohn M.;Van Doesum J.;Ammatuna E.;Marchetti M.;Labrador J.;Zambrotta G. P. M.;Verga L.;Jaksic O.;Nucci M.;Piukovics K.;Cabirta-Touzon A.;Jimenez M.;Arellano E.;Espigado I.;Blennow O.;Nordlander A.;Meers S.;van Praet J.;Aiello T. F.;Garcia-Vidal C.;Fracchiolla N.;Sciume M.;Seval G. C.;Zak P.;Buquicchio C.;Tascini C.;Grafe S. K.;Schonlein M.;Adzic-Vukicevic T.;Bonuomo V.;Cattaneo C.;Nizamuddin S.;Cernan M.;Plantefeve G.;Prin R.;Szotkovski T.;Collins G. P.;Dargenio M.;Petzer V.;Wolf D.;Colovic N.;Prezioso L.;Valkovic T.;Passamonti F.;Mendez G. -A.;Sili U.;Vena A.;Bavastro M.;Limongelli A.;Duarte R. F.;Ledoux M. -P.;Cvetanoski M.;Stojanoski Z.;Machado M.;Batinic J.;Magliano G.;Biernat M. M.;Pantic N.;Poulsen C. B.;Cuccaro A.;Del Principe M. I.;Kulasekararaj A.;Ormazabal-Velez I.;Busca A.;Demirkan F.;Ijaz M.;Klimko N.;Stoma I.;Khostelidi S.;Fernandez N.;Omrani A. S.;Bergantim R.;De Jonge N.;Fouquet G.;Navratil M.;Abu-Zeinah G.;Samarkos M.;Maertens J.;De Ramon C.;Guidetti A.;Magyari F.;Gonzalez-Lopez T. J.;Lahmer T.;Finizio O.;Ali N.;Pinczes L. I.;Lavilla-Rubira E.;Romano A.;Merelli M.;Delia M.;Calbacho M.;Meletiadis J.;Antic D.;Hernandez-Rivas J. -A.;Marques de Almeida J.;Al-Khabori M.;Hoenigl M.;Tisi M. C.;Khanna N.;Barac A.;Eisa N.;Di Blasi R.;Lievin R.;Miranda-Castillo C.;Bahr N. C.;Lamure S.;Papa M. V.;Yahya A.;Aujayeb A.;Novak J.;Erben N.;Fernandez-Galan M.;Ribera-Santa Susana J. -M.;Rinaldi I.;Fazzi R.;Piedimonte M.;Dulery R.;Gonzaga Y.;Soto-Silva A.;Sapienza G.;Serris A.;Drgona;Groh A.;Serrano L.;Gavriilaki E.;Tragiannidis A.;Prattes J.;Coppola N.;Otasevic V.;Mladenovic M.;Mitrovic M.;Miskovic B.;Jindra P.;Zompi S.;Sacchi M. V.;Krekeler C.;Infante M. S.;Garcia-Bordallo D.;Colak G. M.;Mayer J.;Nygaard M.;Hanakova M.;Racil Z.;Bonanni M.;Koehler P.;Rahimli L.;Cornely O. A.;Pagano L.;Martin-Vallejo F. J.;Zdziarski P.;Zarrinfer H.;Wittig J.;Win S.;Wai-Man V.;Visek B.;Vinh D. C.;Vehreschild M.;Varricchio G.;Tsirigotis P.;Torres-Tienza A.;Tanase A. D.;Tafuri A.;Stamouli M.;Sramek J.;Soussain C.;Shirinova A.;Schubert J.;Schalk E.;Salehi M. R.;Saleh M.;Rosati G.;Roldan E.;Reizine F.;Rego M.;Regalado-Artamendi I.;Popova M.;Pinto F.;Philippe L.;Orth H. M.;Ommen H. -B.;Obr A.;Nunez-Martin-Buitrago L.;Noel N.;Neuhann J.;Nadali G.;Nacov J. A.;Munhoz Alburquerque A. M.;Mitra M. E.;Mikulska M.;Mellinghoff S.;Mechtel B.;Martin-Gonzalez J. -A.;Malak S.;Loureiro-Amigo J.;Lorenzo De La Pena L.;Liberti G.;Landau M.;Lacej I.;Kolditz M.;Kho C. S.;Khedr R. A.;Karthaus M.;Karlsson L. K.;Jimenez-Lorenzo M. -J.;Izuzquiza M.;Hoell-Neugebauer B.;Herbrecht R.;Heath C. H.;Guolo F.;Grothe J.;Giordano A.;Gerasymchuk S.;Garcia-Sanz R.;Garcia-Pouton N.;Funke V. A. M.;Fung M.;Flasshove C.;Fianchi L.;Essame J.;Egger M.;Drenou B.;Dragonetti G.;Desole M.;Della Pepa R.;Deau Fischer B.;De Kort E.;De Cabo E.;Danion F.;Daguindau E.;Cushion T.;Cremer L.;Criscuolo M.;Cordini G.;Cingolani A.;Ciceri F.;Chowdhury F. R.;Chelysheva E.;Chauchet A.;Chai L. Y. A.;Ceesay M. M.;Busch E.;Brehon M.;Borducchi D. M. M.;Booth S.;Bologna S.;Berg Venemyr C.;Bailen-Almorox R.;Antoniadou A.;Anastasopoulou A. N.;Altuntas F.
2024
Abstract
Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced. Methods: The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic's start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020–2022). Findings: The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or more doses, as well as encountering COVID-19 in 2022, were associated with improved survival. Interpretation: Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe COVID-19 cases. Funding: Not applicable.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3566868
Citazioni
ND
20
22
ND
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
